“Biological Safety Testing Market Report is set to have rapid growth due high investments in biotechnology, increasing adoption in cancer research and development and increasing number of R&D investments at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report
04 September 2019
Visiongain has launched a new pharma report Biological Safety Testing Market Forecast 2019-2029: By Product, By Application (Vaccines & Therapeutics, Gene Therapy, Stem Cell), By Test, By Region, And Segment Forecasts
The global Biological Safety Testing market is poised for rapid growth between 2019 and 2029. Some factors that are driving market growth include growth in the pharmaceutical and biotechnology industries along with increasing investments and increasing production of new organic products due to the high burden of disease.
The increased need for Biologic products has led to unprecedented growth in the number of biopharmaceutical companies. This growing competition for the development of large-scale therapeutically advanced drugs has forced manufacturers to improve aspects such as productivity, cost efficiency and deviations. Companies are therefore implementing good manufacturing practices that involve thorough biological testing at various levels of production cycles, thus contributing to market growth.
In addition, increasing number of government initiatives to promote biological safety testing products are expected to drive overall market growth in the coming years. High rates of microbial contamination and biological burden during pharmaceutical and biological production should guide government and private organizations to improve underlying biological safety practices.
Leading companies featured in the report include Charles River Laboratories, Lonza Group, Merck Millipore, Wuxi PharmaTech, Avance Biosciences, Cytovance Biologics, Promega Corporation, Thermo Fisher Scientific, Toxikon and Eurofins Scientific
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.
04 December 2019
Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.
04 December 2019
The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
04 December 2019
Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.